Vascular News and Research

RSS

Tryton Medical widens European availability of Side Branch Stent System

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced the launch of the TRYTON Side Branch Stent™ System in Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom. The stent is used to treat bifurcation lesions, the largest unmet need confronting interventional cardiology.

23 Apr 2010

Boston Scientific introduces new Kinetix Guidewire for use in PCI procedures

Boston Scientific Corporation today announced the launch of its new Kinetix™ Guidewire for use in percutaneous coronary intervention (PCI) procedures. Guidewires are small flexible wires physicians use to deliver interventional devices such as drug-eluting stents. The Kinetix Guidewire features a unique micro-cut nitinol sleeve designed for significantly improved torque control compared to conventional spring coil guidewires.

23 Apr 2010

Women and men experience different outcomes at U.S. hospitals: HealthGrades

Women and men experience different outcomes at U.S. hospitals for the same procedures and treatments, according to a new study released today by HealthGrades, the leading independent healthcare ratings organization.

22 Apr 2010

Medtronic acquires Invatec

Moving to expand its product offering, Medtronic, Inc., announced today that it has completed the acquisition of Invatec, a developer of innovative medical technologies for the interventional treatment of cardiovascular disease.

22 Apr 2010

Positive results from initial clinical trial of ClariVein catheter

Results from the initial clinical trial of the ClariVein® catheter, used in a new minimally invasive treatment for varicose veins, have been announced. The device combines mechanical and chemical modalities to accomplish vein treatment in an in-office setting.

22 Apr 2010

FDA approves Medtronic's Complete SE Vascular Stent System for PAD

Broadening the scope of innovation for cardiovascular interventions beyond the heart, Medtronic, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the Complete® SE Vascular Stent System to be used for the treatment of peripheral arterial disease (PAD) in the iliac arteries, major blood vessels within the pelvis that supply blood to the lower extremities.

21 Apr 2010

St. Jude Medical reports 11% increase in first-quarter 2010 net sales

St. Jude Medical, Inc. today reported sales and net earnings for the first quarter ended April 3, 2010.

21 Apr 2010

Abbott's first-quarter worldwide pharmaceutical sales increases by 12.9%

Abbott today announced financial results for the first quarter ended March 31, 2010.

21 Apr 2010

Covidien's second-quarter medical devices sales up 11%

Covidien plc today reported results for the second quarter of fiscal 2010 (January - March 2010).

21 Apr 2010

Researchers demonstrate role of HSP-90 in portal hypertension

Neural vasoregulation represents a rapid and potent mode of altering vascular tone but has not been investigated thoroughly during portal hypertension. Heat shock protein-90 is well-known to act as a molecular chaperone optimizing endothelial and neural NO-synthase enzyme activity and thus, NO production.

21 Apr 2010

Early diagnosis of varicose vein disease leads to simpler treatments and better outcomes

Varicose vein disease is an underappreciated and often misunderstood medical condition, causing many individuals to be misdiagnosed, mistreated - or ignored - resulting in needless suffering and complications from progressively worsening symptoms. Unfortunately, patients typically wait until the disease reaches a more difficult to treat and debilitating stage: they have lifestyle limiting pain, unsightly bulging veins and spider veins, leg swelling or skin ulceration.

21 Apr 2010

New treatment modalities for RCC

Renal cell carcinoma accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy.

21 Apr 2010

Magnetically guided nanoparticles for delivering DNA, cells and drugs

Scientists and engineers have used uniform magnetic fields to drive iron-bearing nanoparticles to metal stents in injured blood vessels, where the particles deliver a drug payload that successfully prevents blockages in those vessels. In this animal study, the novel technique achieved better results at a lower dose than conventional non-magnetic stent therapy.

20 Apr 2010

Study underscores potential for VBL Therapeutics VB-111 as broad-spectrum cancer therapy

VBL Therapeutics today announced positive results from preclinical and Phase 1 studies evaluating the company's lead anti-cancer agent, VB-111 - a first-in-class, targeted biological agent shown to work via dual-action, anti-angiogenic and vascular disruptive mechanism of action - in metastatic cancer. Preclinical data evaluating VB-111 in a comprehensive set of in vivo studies employing the Lewis Lung metastasis mouse model showed the compound to be safe and specific, with a 90% reduction in tumor burden of lung metastases after only one injection.

20 Apr 2010

Low-dose aspirin associated with increased risk of gastrointestinal bleeding

Low-dose aspirin (LDA) is one of the main agents used for the prevention of thromboembolic vascular events, and has the advantages of both low cost and a prolonged duration of antiplatelet action; however, it is associated with a doubling of the risk of gastrointestinal bleeding, even at doses as low as 75 mg daily. The gender differences in the clinical manifestations of LDA-associated gastroduodenal mucosal injury have not been well studied.

20 Apr 2010

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint>Europe, is due to report in the third quarter of 2010.

20 Apr 2010

Podiatric physicians recommend conservative treatments to relieve heel pain

Millions of Americans complain of heel pain, which is usually caused by plantar fasciitis. Plantar fasciitis is a condition in which the plantar fascia (ligament that runs from your heel to the toes) becomes inflamed. This condition can be very painful and cause a considerable amount of suffering.

20 Apr 2010

Jennerex presents positive interim data from Phase 2 clinical trial of JX-594 for HCC at 45th EASL

Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced the presentation of positive interim data from its randomized Phase 2 clinical trial using JX-594 for the treatment of advanced hepatocellular carcinoma (HCC), or liver cancer, at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria.

19 Apr 2010

Caliper Life Sciences introduces Quantum FX stand-alone microCT system for preclinical imaging

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery, life sciences research and molecular diagnostics, today announced the Quantum FX, a stand-alone microCT system for preclinical imaging. Introduced at the American Association for Cancer Research Annual Meeting 2010, the Quantum FX is a low dose, microCT system that provides researchers with a 3-dimensional anatomical view of disease activity, tumor development and therapeutic response over multiple time points during the course of a study.

19 Apr 2010

Surgery still the only measure to cure RCC

Renal cell carcinoma (RCC) accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy.

19 Apr 2010